146 related articles for article (PubMed ID: 28550907)
1. Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.
Ito C; Nishizuka SS; Ishida K; Uesugi N; Sugai T; Tamura G; Koeda K; Sasaki A
J Surg Res; 2017 May; 212():195-204. PubMed ID: 28550907
[TBL] [Abstract][Full Text] [Related]
2. Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
Fang WL; Huang KH; Lan YT; Lin CH; Chang SC; Chen MH; Chao Y; Lin WC; Lo SS; Li AF; Wu CW; Chiou SH; Shyr YM
Oncotarget; 2016 Feb; 7(5):6201-20. PubMed ID: 26701847
[TBL] [Abstract][Full Text] [Related]
3. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.
Shi J; Yao D; Liu W; Wang N; Lv H; Zhang G; Ji M; Xu L; He N; Shi B; Hou P
BMC Cancer; 2012 Feb; 12():50. PubMed ID: 22292935
[TBL] [Abstract][Full Text] [Related]
4. Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer.
Tran TN; Brettingham-Moore K; Duong CP; Mitchell C; Clemons NJ; Phillips WA
J Surg Oncol; 2013 Aug; 108(2):113-20. PubMed ID: 23813545
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
6. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
[TBL] [Abstract][Full Text] [Related]
7. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
Harada K; Baba Y; Shigaki H; Ishimoto T; Miyake K; Kosumi K; Tokunaga R; Izumi D; Ohuchi M; Nakamura K; Kiyozumi Y; Kurashige J; Iwatsuki M; Miyamoto Y; Sakamoto Y; Yoshida N; Watanabe M; Baba H
BMC Cancer; 2016 Jul; 16():400. PubMed ID: 27388016
[TBL] [Abstract][Full Text] [Related]
10. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
[TBL] [Abstract][Full Text] [Related]
12. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
[TBL] [Abstract][Full Text] [Related]
13. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Prognostic Significance of PIK3CA Mutation and CNV Status and Phosphorylated AKT Expression in Patients With Cervical Cancer Treated With Primary Surgery.
Martell K; McIntyre JB; Abedin T; Kornaga EN; Chan AMY; Enwere E; Köbel M; Dean ML; Phan T; Ghatage P; Lees-Miller SP; Doll CM
Int J Gynecol Pathol; 2024 Mar; 43(2):158-170. PubMed ID: 37668363
[TBL] [Abstract][Full Text] [Related]
15. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without
Fang WL; Huang KH; Chang SC; Lin CH; Chen MH; Chao Y; Lo SS; Li AF; Wu CW; Shyr YM
Oncologist; 2019 Sep; 24(9):e845-e853. PubMed ID: 30796154
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.
Kato S; Iida S; Higuchi T; Ishikawa T; Takagi Y; Yasuno M; Enomoto M; Uetake H; Sugihara K
Int J Cancer; 2007 Oct; 121(8):1771-8. PubMed ID: 17590872
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
Liu JF; Zhou XK; Chen JH; Yi G; Chen HG; Ba MC; Lin SQ; Qi YC
World J Gastroenterol; 2010 Oct; 16(39):4986-91. PubMed ID: 20954287
[TBL] [Abstract][Full Text] [Related]
20. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival.
Rogers HA; Mayne C; Chapman RJ; Kilday JP; Coyle B; Grundy RG
Clin Cancer Res; 2013 Dec; 19(23):6450-60. PubMed ID: 24077346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
